Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
- 19 June 2006
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 24 (4) , 181-188
Abstract
The importance of arsenic trioxide (As2O3) has been underscored over the last decade due to its efficacy against acute promyelocytic leukemia (APL), a disease in which this agent has been associated with complete hematologic and molecular remission rates of 87% and 83%, respectively. The different molecular mechanisms of action of As2O3 suggest its applicability in hematologic malignancies other than APL. However, responses obtained thus far have consisted of improvements in signs and symptoms without the elimination of a given disease. Toxicities derived from As2O3 are significant but manageable and reversible. However, the risk/benefit ratio of As2O3 in hematologic malignancies other than APL is still unclear. The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 52 references indexed in Scilit:
- A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patientsLeukemia, 2004
- Phenylarsine Oxide (PAO) More Intensely Induces Apoptosis in Acute Promyelocytic Leukemia and As2O3-Resistant APL Cell Lines than As2O3by Activating the Mitochondrial PathwayLeukemia & Lymphoma, 2004
- Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaBritish Journal of Haematology, 2004
- Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignanciesCancer, 2004
- Acute promyelocytic leukaemia:a reviewExpert Opinion on Pharmacotherapy, 2003
- Clinical activity of arsenic trioxide in Burkitt-like lymphomaLeukemia, 2003
- Clinical activity of arsenic trioxide for the treatment of multiple myelomaLeukemia, 2002
- Arsenic Trioxide in Multiple MyelomaThe Cancer Journal, 2002
- Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cellsEuropean Journal of Haematology, 1992
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976